Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $11.24bn (+5.7%); operating margin -2.7%; net loss $957.0m.
Continuing operations; operating loss after impairment and restructuring charges.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Oct 2025: A securities class action filed in Illinois alleges Baxter misled investors about the safety of its Novum IQ large-volume infusion pump; Baxter said it intends to vigorously defend itself. Its shares fell over 20% in Jul 2025 after it paused pump installations.
Data breaches, cyber incidents, regulator action and assurance status.
Nov 2025: HealthExec reported that the FDA had issued a full recall of Baxter Life2000 ventilators because of a serious cybersecurity flaw. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Jul 2025: The FDA issued an early alert on Baxter's Novum IQ large-volume infusion pumps, which can under-infuse after large rate increases; Baxter had reported 79 serious injuries and two deaths linked to the issue and issued customer instructions.
Contract delivery, go-lives, terminations and disputes.
Jul 2025: Baxter paused planned new installations of its Novum IQ large-volume infusion pump while it addressed a flow-rate problem; existing pumps remained in use under updated instructions.